glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models What do you do with

Guideline source: BMJ/MAGIC Group Evidence rating system used

As most of the available evidence stems from in vitro and preclinical studies, there remains a need for long-term and in vivo research to substantiate these findings and assess their translational relevance

Sample Weekly Schedule: GLP-1 Training and Recovery Total weekly working sets per muscle group: 10 to 14 Total training days: 3 Total rest or active recovery days: 4 This is a significant departure from the 4 to 5 day splits many lifters are used to

For the efficacy estimand, the LSM change in HbA1c from baseline at week 52 as the primary endpoint was 2.24%, 2.43%, and 2.58% with tirzepatide 5, 10, and 15 mg, respectively, versus 1.44% with insulin glargine

To date, however, no studies performed in humans are available